Clinical trials: Radiation-Induced Dermatitis
Oral Mucositis Due to Radiation, Radiation Dermatitis
Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis
The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head \& neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis…
- Trial name
- SafePBM (NCT03988556)
- Testing
- Photobiomodulation using CareMin650 at 6 Joules (curative intent), Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
- Where
- 5 sites in France
- Volunteers
- 72 people
- Sponsor
- NeoMedLight
Radiation Dermatitis
Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Routinely collected data on radiation-induced skin toxicity from 2010 to 2022 will be retrospectively analyzed. Data will be split into two cohorts: patients that received 1) StrataXRT and 2) standard of care.
- Trial name
- NCT05810194
- Testing
- StrataXRT, Calendula, Aquaphor
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Stratpharma AG
Radiodermatitis, Dermatitis, Radiation-Induced
Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.
This is a post marketing, interventional, randomized, single-center, prospective, controlled study, for the evaluation of the clinical performance and tolerability of a cream-based medical device (DermoRelizemaTM cream) in the…
- Trial name
- DRESDA (NCT04483856)
- Testing
- DermoRelizema cream, Dexeryl
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Relife Italia S.r.l.
Radiation Dermatitis
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
The aim of this study is to assess the efficacy and safety of StrataXRT® in comparison to standard of care (defined using the Common Terminology Criteria for Adverse Events [CTCAE], version 5.0) by assessing the severity of…
- Trial name
- NCT05553392
- Testing
- StrataXRT, Aquaphor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stratpharma AG
Breast Cancer
Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis
This is a single-center, open-label, randomized, prospective study evaluating the safety and efficacy of HO/02/02 20µg topically applied daily for 15 minutes (with gauze) on treatment fields vs.
- Trial name
- ARD (NCT01923220)
- Testing
- HO/02/02 20µg, Aloe Vera Jel
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- HealOr
Radiodermatitis
Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy
This study, a nonrandomized open-label safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.
- Trial name
- NCT01544504
- Testing
- Norepinephrine
- Where
- United States
- Sponsor
- ProCertus BioPharm, Inc
Breast Cancer, Radiation Dermatitis
A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer
The purpose of this study is to evaluate the effects of topical R1 and R2 for prophylaxis of acute radiation dermatitis in patients with breast cancer receiving radiotherapy.
- Conditions
- Breast Cancer, Radiation Dermatitis, Erythema
- Trial name
- NCT01597921
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Water-Jel
Radiodermatitis, Oncology
Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.
Testing the efficacy of the Jalosome® Soothing gel in 2 or 3 grade radiodermatitis healing in oncological patients. The investigators would like to know also the efficacy of the device on quality of life and pain.
- Conditions
- Radiodermatitis, Oncology, Quality of Life, Pain
- Trial name
- NCT04692389
- Testing
- Jalosome soothing gel
- Where
- Switzerland
- Sponsor
- Welcare Industries SpA
Alopecia, Radiodermatitis
Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy
The study will evaluate the safety of topical norepinephrine in head and neck cancer patients who are receiving treatment with intensity modulated radiotherapy (IMRT).
- Trial name
- NCT01367990
- Testing
- Norepinephrine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ProCertus BioPharm, Inc
Radiodermatitis
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
This study, a nonrandomized open-label Phase I safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy.
- Trial name
- NCT01263366
- Testing
- Norepinephrine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- ProCertus BioPharm, Inc
Radiodermatitis
Topical Use of Difinsa53™ to Prevent Radiation Dermatitis
Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying, ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing whole breast radiation.
- Trial name
- NCT02534129
- Testing
- Difinsa53, Aquaphor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- ProTechSure Scientific, Inc.
Radiation-induced Dermatitis
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
The objective of this study is to evaluate the safety and efficacy of ST266 in treating radiation burns of the skin in patients undergoing treatments for breast cancer and to compare ST266 treated burns with those treated with…
- Trial name
- NCT01714973
- Testing
- ST266
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Radiodermatitis, Quality of Life
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation dermatitis in breast and head \& neck cancer patients.
- Trial name
- NCT03255980
- Testing
- Xonrid® gel, Standard of Care
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Helsinn Healthcare SA
Radiation Dermatitis
StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis
Current clinical practice for preventing and treating radiation dermatitis across Queensland (QLD) Health Radiation Oncology departments involves the application of aqueous cream daily to the skin of the treatment site…
- Trial name
- NCT05450848
- Testing
- StrataXRT, Sorbolene
- Where
- 2 sites in Australia
- Volunteers
- 105 people
- Sponsor
- Stratpharma AG
Radiation Induced Dermatitis
Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer
The standard treatment for early-stage breast cancer is breast-conserving surgery followed by adjuvant radiation therapy to the whole breast.
- Trial name
- NCT01513278
- Testing
- APN201
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Apeiron Biologics
Radiation Dermatitis
Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis
The main purpose of this study is to demonstrate the safety and efficacy of KAM1403 GEL in reducing the symptoms of mild to moderate Radiation Dermatitis.
- Trial name
- kam1403 (NCT02051907)
- Testing
- KAM1403 Gel, aloevera gel
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Kamedis Ltd.
Radiodermatitis; Acute
A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer
This clinical trial is testing a new skin gel called GR1014-CG to evaluate its safety and see if it can help prevent or reduce skin irritation (such as redness, soreness, etc.) caused by radiation therapy (RT) after…
- Trial name
- GuARD (NCT07192588)
- Testing
- GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 273 people
- Sponsor
- Graegis Pharmaceuticals Ltd
Radiation Dermatitis
LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis.
- Trial name
- NCT04261387
- Testing
- LUT014 Gel
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lutris Pharma Ltd.
Radiation-induced Dermatitis
Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.
Primary objective To investigate the effectiveness of Jalosome® compared with placebo in the prevention and treatment of RID in patients with HNC undergoing RT.
- Trial name
- JALOSOME-01 (NCT05284487)
- Testing
- Jalosome® soothing gel
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Welcare Industries SpA
Radiodermatitis
Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
This trial is designed as a multicenter, double-blinded, randomized, placebo controlled study to assess the safety and efficacy of JBM-TC4 for the prevention and treatment of acute radiation-induced dermatitis in breast cancer…
- Trial name
- NCT02289365
- Testing
- 2000 mg of JBM-TC4 per day, 3000 mg of JBM-TC4 per day, 3000 mg of PEG-400 per day
- Where
- 3 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Joben Bio-Medical Co., Ltd.